N-(3,5-diimino-2-methyl-7-thia-2,4,6-triazanonan-9-yl)acetamide

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-(3,5-diimino-2-methyl-7-thia-2,4,6-triazanonan-9-yl)acetamide
• 英文别名: N-[2-[[amino-[[amino(dimethylamino)methylidene]amino]methylidene]amino]sulfanylethyl]acetamide
• 化学式: C₈H₁₈N₆OS
• 分子量: 246.337
• InChiKey: APXRXLZDZWCNHN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.3
• 重原子数：
  16
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  134
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  N-(2-((1,3-dioxoisoindolin-2-yl)thio)ethyl)acetamide 、 二甲双胍 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 N-(3,5-diimino-2-methyl-7-thia-2,4,6-triazanonan-9-yl)acetamide
  参考文献：
  名称：

  [EN] METFORMIN DERIVATIVES
  [FR] DÉRIVÉS DE LA METFORMINE

  摘要：

  公开号：

  WO2016044433A3

文献信息

• Metformin derivatives
  申请人：BioPharma Works LLC

  公开号：US10017529B2

  公开（公告）日：2018-07-10

  The present invention relates to novel biguanide derivatives including their pharmaceutically acceptable salts. The invention also relates processes for the preparation of, intermediates used in the preparation of, pharmaceutical compositions containing and the uses of such compounds in treating disorders such as diabetes.

  本发明涉及新型双胍衍生物，包括其药学上可接受的盐类。本发明还涉及制备过程、制备过程中使用的中间体、含有此类化合物的药物组合物以及此类化合物在治疗糖尿病等疾病中的用途。
• Methods and compositions for treating cancer
  申请人：THE UNIVERSITY OF CHICAGO

  公开号：US10888569B1

  公开（公告）日：2021-01-12

  The disclosure relates to improved therapeutic methods for treating cancer patients. The methods include a method for treating cancer in a subject comprising administering an effective amount of a BACH1 inhibitor and an ETC inhibitor to the subject. Further aspects of the disclosure relate to a method for treating cancer in a subject comprising: administering a first therapeutic regimen comprising an ETC inhibitor to the subject after a biological sample from the subject was determined to have a decreased or substantially the same level of expression of BACH1 relative to a control sample or to a cut-off value; wherein the first therapeutic regimen excludes a BACH1 inhibitor; or administering a second therapeutic regimen comprising a BACH1 inhibitor and an ETC inhibitor to the subject after a biological sample from the subject was determined to have an increased level of expression of BACH1 relative to a control sample or a cut-off value.

  本公开涉及治疗癌症患者的改进治疗方法。这些方法包括治疗受试者癌症的方法，该方法包括向受试者施用有效量的 BACH1 抑制剂和 ETC 抑制剂。本公开的其他方面涉及一种治疗受试者癌症的方法，包括在确定受试者的生物样本相对于对照样本或临界值具有降低或基本相同的BACH1表达水平之后，向受试者施用包含ETC抑制剂的第一治疗方案；其中第一治疗方案不包括BACH1抑制剂；或 在确定受试者的生物样本相对于对照样本或临界值具有升高的BACH1表达水平之后，向受试者施用包含BACH1抑制剂和ETC抑制剂的第二治疗方案。
• METFORMIN DERIVATIVES
  申请人：BioPharma Works LLC

  公开号：US20170247400A1

  公开（公告）日：2017-08-31

  The present invention relates to novel biguanide derivatives including their pharmaceutically acceptable salts. The invention also relates processes for the preparation of, intermediates used in the preparation of, pharmaceutical compositions containing and the uses of such compounds in treating disorders such as diabetes.
• [EN] METFORMIN DERIVATIVES<br/>[FR] DÉRIVÉS DE LA METFORMINE
  申请人：BIOPHARMA WORKS

  公开号：WO2016044433A3

  公开（公告）日：2016-06-16